According
to the recently published report Midkine
- Pipeline Review, H1 2018 Midkine (Amphiregulin Associated Protein or
Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK)
pipeline Target constitutes close to 8 molecules. Out of which approximately 6
molecules are developed by companies and remaining by the
universities/institutes.
Midkine
(Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite
Outgrowth Promoting Factor 2 or MDK) - Midkine (MDK) or neurite
growth-promoting factor 2 is a protein encoded by the MDK gene. It binds to
anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation
of the insulin receptor substrate, activation of mitogen-activated protein
kinase and PI3-kinase and the induction of cell proliferation. It is involved
in neointima formation after arterial injury and early fetal adrenal gland
development.
The
report 'Midkine - Pipeline Review, H1 2018' outlays comprehensive information
on the Midkine (Amphiregulin Associated Protein or Midgestation And Kidney
Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted therapeutics,
complete with analysis by indications, stage of development, mechanism of
action (MoA), route of administration (RoA) and molecule type; that are being
developed by Companies / Universities.
It
also reviews key players involved in Midkine (Amphiregulin Associated Protein
or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or
MDK) targeted therapeutics development with respective active and dormant or
discontinued projects. Currently, the molecules developed by companies in
Preclinical stages are 6 respectively. Similarly, the universities portfolio in
Preclinical stages comprises 2 molecules, respectively. Report covers products
from therapy areas Oncology, Genito Urinary System And Sex Hormones,
Immunology, Metabolic Disorders, Gastrointestinal, Musculoskeletal Disorders,
Cardiovascular and Respiratory which include indications Inflammation, Diabetic
Nephropathy, Kidney Fibrosis, Liver Fibrosis, Non-Small Cell Lung Cancer, Acute
Renal Failure (ARF) (Acute Kidney Injury), Autoimmune Disorders, Bone Disorders,
Bone Fracture, Chronic Kidney Disease (Chronic Renal Failure), Fibrosis, Focal
Segmental Glomerulosclerosis (FSGS), Glioblastoma Multiforme (GBM),
Glomerulonephritis, Ischemia Reperfusion Injury, Kidney Disease, Lung Disease,
Neuroblastoma, Osteoporosis, Osteosarcoma, Prostate Cancer, Solid Tumor and
Squamous Non-Small Cell Lung Cancer.
The
report provides a snapshot of the global therapeutic landscape for Midkine
(Amphiregulin Associated Protein or Midgestation and Kidney Protein or Neurite
Outgrowth Promoting Factor 2 or MDK)
The
report reviews Midkine (Amphiregulin Associated Protein or Midgestation and
Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted
therapeutics under development by companies and universities/research
institutes based on information derived from company and industry-specific
sources
The
report covers pipeline products based on various stages of development ranging
from pre-registration till discovery and undisclosed stages
The
report features descriptive drug profiles for the pipeline products which
includes, product description, descriptive MoA, R&D brief, licensing and
collaboration details & other developmental activities
The
report reviews key players involved in Midkine (Amphiregulin Associated Protein
or Midgestation and Kidney Protein or Neurite Outgrowth Promoting Factor 2 or
MDK) targeted therapeutics and enlists all their major and minor projects
The
report assesses Midkine (Amphiregulin Associated Protein or Midgestation and
Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK) targeted
therapeutics based on mechanism of action (MoA), route of administration (RoA)
and molecule type
The
report summarizes all the dormant and discontinued pipeline projects
The
report reviews latest news and deals related to Midkine (Amphiregulin Associated
Protein or Midgestation and Kidney Protein or Neurite Outgrowth Promoting
Factor 2 or MDK) targeted therapeutics
To know, more click on the link below:
Related Reports:
https://www.kenresearch.com/healthcare/pharmaceuticals/midkine-amphiregulin-associated/49986-91.html
Contact Us:
Ken
Research
Ankur
Gupta, Head Marketing & Communications
0124-4230204